Blepharitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 2022 | 60 pages | ID: BF98E29C6B42EN
Global Markets Direct

Abstracts

Blepharitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Drugs In Development, 2022, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Blepharitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 7 and 2 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Blepharitis - Overview
Blepharitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Blepharitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Blepharitis - Companies Involved in Therapeutics Development
Blepharitis - Drug Profiles
Blepharitis - Dormant Projects
Blepharitis - Product Development Milestones
Featured News & Press Releases
Feb 08, 2022: Tarsus to host eye care leaders webcast on unmet needs in demodex blepharitis and potential of TP-03
Feb 02, 2022: Tarsus Completes enrollment for the pivotal phase 3 Saturn-2 trial of TP-03 to treat demodex blepharitis and secures $175 million credit facility
Nov 30, 2021: Nicox’s positive post hoc results from NCX 4251 phase 2b Mississippi trial suggest path forward in dry eye disease
Nov 17, 2021: Nicox is granted patent for blepharitis product candidate NCX 4251 in Europe
Nov 04, 2021: Tarsus Pharmaceuticals, presents data from two pioneering studies on the prevalence and impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting
Aug 31, 2021: AxeroVision announces phase 2 results for AXR-270 for treatment of dry eye disease associated with MGD
Jul 24, 2021: Tarsus Pharmaceuticals presents new Saturn-1 pivotal trial data and Titan real-world prevalence study results at ASCRS 2021
Jul 02, 2021: Nicox announces last patient completed NCX 4251 Mississippi phase 2b blepharitis trial
Jun 21, 2021: Tarsus Pharmaceuticals announces positive results of Saturn-1 pivotal trial evaluating TP-03 for the treatment of demodex blepharitis
Jun 18, 2021: Tarsus Pharmaceuticals schedules conference call and webcast to announce saturn-1 phase 2b/3 pivotal trial results for TP-03 for the treatment of Demodex Blepharitis
Jun 01, 2021: Nicox’s completes pre-defined enrollment of NCX 4251 Mississippi phase 2b Blepharitis trial
May 06, 2021: Tarsus Pharmaceuticals initiates Saturn-2, second pivotal phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis
May 03, 2021: Tarsus Pharmaceuticals presents results of pioneering Atlas study at ARVO 2021 annual meeting demonstrating the functional and psychosocial impact of demodex blepharitis
Apr 23, 2021: Nicox’s NCX 4251 Mississippi Phase 2b blepharitis trial reaches 50% enrollment
Mar 17, 2021: Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Blepharitis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Blepharitis - Pipeline by Aerie Pharmaceuticals Inc, 2022
Blepharitis - Pipeline by Aperta Biosciences LLC, 2022
Blepharitis - Pipeline by AxeroVision Inc, 2022
Blepharitis - Pipeline by Azura Ophthalmics Pty Ltd, 2022
Blepharitis - Pipeline by Formosa Pharmaceuticals Inc, 2022
Blepharitis - Pipeline by Hovione FarmaCiencia SA, 2022
Blepharitis - Pipeline by Merck & Co Inc, 2022
Blepharitis - Pipeline by NicOx SA, 2022
Blepharitis - Pipeline by NTC srl, 2022
Blepharitis - Pipeline by Premark Pharma GmbH, 2022
Blepharitis - Pipeline by Quorum Innovations LLC, 2022
Blepharitis - Pipeline by Santen Pharmaceutical Co Ltd, 2022
Blepharitis - Pipeline by Sol-Gel Technologies Ltd, 2022
Blepharitis - Pipeline by Tarsus Pharmaceuticals Inc, 2022
Blepharitis - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Blepharitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022